New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 13, 2014
07:32 EDTHZNP, POZNHorizon Pharma, POZEN announce USPTO Notice of Allowance for VIMOVO
Horizon Pharma (HZNP) announced that POZEN (POZN), has received a Notice of Allowance from the United States Patent and Trademark Office for U.S. patent application number 14/045,156 entitled "Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs" that covers Horizon and POZEN'S U.S. approved product VIMOVO delayed release tablets.
News For HZNP;POZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 31, 2015
12:42 EDTHZNPAnalysts bullish on Horizon after Hyperion acquisition
A number of analysts were upbeat on the outlook for drugmaker Horizon Pharma (HZNP) after the company yesterday announced that it had agreed to acquire fellow drugmaker Hyperion Therapeutics (HPTX). WHAT'S NEW: Piper Jaffray analyst David Amsellem upgraded Horizon to Overweight from Neutral, saying that the acquisition of Hyperion is positive because it diversifies Horizon's products. The deal should increase Hyperion's price to earnings ratio because it expands the company's offerings beyond assets focused on primary care, while providing the company with a very well-positioned product, Ravicti, Amsellem explained. An ultra-orphan drug used to treat urea cycle disorders, Ravicti is a game changer, as only half of the patients with the disease have been diagnosed, the analyst stated. Moreover, it is far more "patent-friendly" than its competitor, Buphenyl, Amsellem reported. Over half of Buphenyl's patients have converted to Horizon's Ravicti and the latter drug has significant room for growth, according to the analyst, who set a $31 price target on Horizon. Also upbeat on Horizon after the deal was JMP Securities analyst Oren Livnat. The deal is positive because it strengthens Hyperion's orphan drug business, wrote Livnat, who increased his price target on the name to $31 from $25. Additionally, the transaction is likely to increase Horizon's earnings per share by 40c, in-line with the company's guidance, the analyst predicted. Although Horizon may ultimately have to pay a higher price for Hyperion, Horizon could pay slightly more and still obtain value from the deal, the analyst stated. He kept an Outperform rating on the stock. PRICE ACTION: In early afternoon trading, Horizon was little changed at $25.75 and Hyperion lost 0.5% to $45.80.
10:01 EDTHZNPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:47 EDTHZNPHorizon Pharma cost savings view seems conservative, says Brean Capital
Brean Capital believes Horizon Pharma's (HPZN) guidance on annualized cost savings from its deal with Hyperion Therapeutics (HPTX) is conservative. The firm noted Horizon executes well on M&A, as it paid a reasonable price for Hyperion. Brean Capital reiterated its Buy rating and raised its price target to $33 from $27 on Horizon Pharma shares.
07:44 EDTHZNPHorizon Pharma price target raised to $31 from $25 at JMP Securities
Subscribe for More Information
07:32 EDTHZNPHorizon Pharma estimates need to come up, says UBS
Subscribe for More Information
06:34 EDTHZNPHyperion Therapeutics downgraded to Hold from Buy at Cantor
Cantor Fitzgerald downgraded Hyperion Therapeutics (HPTZ) to Hold citing the takeover by Horizon Pharma (HZNP) as it does not expect a competing bidder to emerge. Cantor raised its price target for shares to $46 from $35.
06:25 EDTHZNPHorizon Pharma upgraded to Overweight from Neutral at Piper Jaffray
Subscribe for More Information
05:52 EDTHZNPHorizon Pharma upgraded to Overweight from Neutral at Piper Jaffray
Subscribe for More Information
March 30, 2015
16:22 EDTHZNPOn The Fly: Closing Wrap
Subscribe for More Information
13:48 EDTHZNPHyperion Therapeutics downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
12:22 EDTHZNPOn The Fly: Midday Wrap
Subscribe for More Information
11:49 EDTHZNPStreet Check: Hyperion bought after Brean noted takeout potential last month
Subscribe for More Information
11:02 EDTHZNPHyperion Therapeutics downgraded to Hold from Buy at Brean Capital
Brean Capital downgraded Hyperion Therapeutics (HPTX) citing the takeover by Horizon Pharma (HZNP). Brean views the buyout price as "reasonable and fair."
10:12 EDTHZNPHigh option volume stocks
Subscribe for More Information
07:02 EDTHZNPHorizon Pharma to host conference call
Conference call to discuss the acquisition of Hyperion Therapeutics (HPTX) will be held on March 30 at 8 am. Webcast Link
06:04 EDTHZNPHorizon Pharma to acquire Hyperion Therapeutics for $46.00 per share
Subscribe for More Information
06:01 EDTHZNPHorizon Pharma to acquire Hyperion Therapeutics for $46.00 per share
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use